MED13L (mediator complex subunit 13-like) is a component of the mediator complex, which functions as a regulator for gene transcription. Since gene abnormalities in MED13L are responsible for neurodevelopmental disorders, MED13L is presumed to play an essential role in brain development. In this study, we prepared a specific antibody against MED13L, anti-MED13L, and analyzed its expression profile in mouse tissues with focusing on the central nervous system. In Western blotting, MED13L exhibited a tissue-dependent expression profile in the adult mouse and was expressed in a developmental stage-dependent manner in brain. In immunofluorescence analyses, MED13L was at least partially colocalized with pre- and post-synaptic markers, synaptophysin, and PSD95, in primary cultured hippocampal neurons. Immunohistochemical analyses revealed that MED13L was relatively highly expressed in ventricular zone surface of cerebral cortex, and was also located both in the cytoplasm and nucleus of neurons in the cortical plate at embryonic day 14. Then, MED13L showed diffuse cytoplasmic distribution throughout the cerebral cortex at the postnatal day (P) 30. In addition, MED13L appeared to be localized in cell type- and developmental stage-specific manners in the hippocampus and cerebellum. These results suggest that MED13L is involved in the development of the central nervous system and synaptic function.

1.
Liu
X
,
Bushnell
DA
,
Kornberg
RD
.
RNA polymerase II transcription: structure and mechanism
.
Biochim Biophys Acta
.
2013 Jan
;
1829
(
1
):
2
8
. .
2.
Casamassimi
A
,
Napoli
C
.
Mediator complexes and eukaryotic transcription regulation: an overview
.
Biochimie
.
2007 Dec
;
89
(
12
):
1439
46
. .
3.
Taatjes
DJ
.
The human mediator complex: a versatile, genome-wide regulator of transcription
.
Trends Biochem Sci
.
2010 Jun
;
35
(
6
):
315
22
. .
4.
Malik
S
,
Roeder
RG
.
The metazoan mediator co-activator complex as an integrative hub for transcriptional regulation
.
Nat Rev Genet
.
2010 Nov
;
11
(
11
):
761
72
. .
5.
Lewis
BA
,
Reinberg
D
.
The mediator coactivator complex: functional and physical roles in transcriptional regulation
.
J Cell Sci
.
2003 Sep 15
;
116
(
Pt 18
):
3667
75
. .
6.
Ito
H
,
Morishita
R
,
Noda
M
,
Iwamoto
I
,
Nagata
K-I
.
Biochemical and morphological characterization of SEPT1 in mouse brain
.
Med Mol Morphol
.
2020 Mar 7
;
134
:
491
10
.
7.
Hanai
N
,
Nagata
K
,
Kawajiri
A
,
Shiromizu
T
,
Saitoh
N
,
Hasegawa
Y
, et al.
Biochemical and cell biological characterization of a mammalian septin, Sept11
.
FEBS Lett
.
2004 Jun 18
;
568
(
1–3
):
83
8
. .
8.
Nagata
KI
,
Puls
A
,
Futter
C
,
Aspenstrom
P
,
Schaefer
E
,
Nakata
T
, et al.
The MAP kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3
.
EMBO J
.
1998 Jan 2
;
17
(
1
):
149
58
. .
9.
Hamada
N
,
Fujita
Y
,
Tanaka
A
,
Naoi
M
,
Nozawa
Y
,
Ono
Y
, et al.
Metabolites of sesamin, a major lignan in sesame seeds, induce neuronal differentiation in PC12 cells through activation of ERK1/2 signaling pathway
.
J Neural Transm
.
2009 Jun 16
;
116
(
7
):
841
52
. .
10.
Hamada
N
,
Iwamoto
I
,
Kawamura
N
,
Nagata
K-I
.
Heterotrimeric G-protein, Gi1, is involved in the regulation of proliferation, neuronal migration, and dendrite morphology during cortical development in vivo
.
J Neurochem
.
2020 Oct 6
;
418
:
475
.
11.
Ito
H
,
Morishita
R
,
Mizuno
M
,
Kawamura
N
,
Tabata
H
,
Nagata
KI
.
Biochemical and morphological characterization of a neurodevelopmental disorder-related mono-ADP-ribosylhydrolase, MACRO domain containing 2
.
Dev Neurosci
.
2018
;
40
(
3
):
278
87
. .
12.
Asadollahi
R
,
Oneda
B
,
Sheth
F
,
Azzarello-Burri
S
,
Baldinger
R
,
Joset
P
, et al.
Dosage changes of MED13L further delineate its role in congenital heart defects and intellectual disability
.
Eur J Hum Genet
.
2013 Oct
;
21
(
10
):
1100
4
. .
13.
Adegbola
A
,
Musante
L
,
Callewaert
B
,
Maciel
P
,
Hu
H
,
Isidor
B
, et al.
Redefining the MED13L syndrome
.
Eur J Hum Genet
.
2015 Oct
;
23
(
10
):
1308
17
. .
14.
Cafiero
C
,
Marangi
G
,
Orteschi
D
,
Ali
M
,
Asaro
A
,
Ponzi
E
, et al.
Novel de novo heterozygous loss-of-function variants in MED13L and further delineation of the MED13L haploinsufficiency syndrome
.
Eur J Hum Genet
.
2015 Nov
;
23
(
11
):
1499
504
. .
15.
van Haelst
MM
,
Monroe
GR
,
Duran
K
,
van Binsbergen
E
,
Breur
JM
,
Giltay
JC
, et al.
Further confirmation of the MED13L haploinsufficiency syndrome
.
Eur J Hum Genet
.
2015 Jan
;
23
(
1
):
135
8
. .
16.
Yamamoto
T
,
Shimojima
K
,
Ondo
Y
,
Shimakawa
S
,
Okamoto
N
.
MED13L haploinsufficiency syndrome: a de novo frameshift and recurrent intragenic deletions due to parental mosaicism
.
Am J Med Genet A
.
2017 May
;
173
(
5
):
1264
9
. .
17.
Gordon
CT
,
Chopra
M
,
Oufadem
M
,
Alibeu
O
,
Bras
M
,
Boddaert
N
, et al.
MED13L loss-of-function variants in two patients with syndromic Pierre Robin sequence
.
Am J Med Genet A
.
2018 Jan
;
176
(
1
):
181
6
. .
18.
Tørring
PM
,
Larsen
MJ
,
Brasch-Andersen
C
,
Krogh
LN
,
Kibæk
M
,
Laulund
L
, et al.
Is MED13L-related intellectual disability a recognizable syndrome?
Eur J Med Genet
.
2019 Feb
;
62
(
2
):
129
36
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.